Switch theme
Sign up to access all valuation multiples
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
2018
107
LTM Revenue $0.5M
Last FY EBITDA -$71.9M
-$36.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neurogene has a last 12-month revenue (LTM) of $0.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Neurogene achieved revenue of $0.9M and an EBITDA of -$71.9M.
Neurogene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neurogene valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | XXX | $0.9M | XXX | XXX | XXX |
| Gross Profit | $0.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$71.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -7771% | XXX | XXX | XXX |
| EBIT | -$95.1M | XXX | -$82.6M | XXX | XXX | XXX |
| EBIT Margin | -17539% | XXX | -8930% | XXX | XXX | XXX |
| Net Profit | -$85.8M | XXX | -$75.1M | XXX | XXX | XXX |
| Net Margin | -15828% | XXX | -8124% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Neurogene's stock price is $17.
Neurogene has current market cap of $243M, and EV of -$36.5M.
See Neurogene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$36.5M | $243M | XXX | XXX | XXX | XXX | $-4.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Neurogene has market cap of $243M and EV of -$36.5M.
Neurogene's trades at -39.5x EV/Revenue multiple, and 0.5x EV/EBITDA.
Equity research analysts estimate Neurogene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neurogene has a P/E ratio of -2.8x.
See valuation multiples for Neurogene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $243M | XXX | $243M | XXX | XXX | XXX |
| EV (current) | -$36.5M | XXX | -$36.5M | XXX | XXX | XXX |
| EV/Revenue | -67.4x | XXX | -39.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/Gross Profit | -67.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.8x | XXX | -3.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeurogene's revenue per employee in the last FY averaged $9K, while opex per employee averaged $0.8M for the same period.
Neurogene's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neurogene's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Neurogene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -7771% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $9K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6586% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 9030% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neurogene acquired XXX companies to date.
Last acquisition by Neurogene was XXXXXXXX, XXXXX XXXXX XXXXXX . Neurogene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Neurogene founded? | Neurogene was founded in 2018. |
| Where is Neurogene headquartered? | Neurogene is headquartered in United States of America. |
| How many employees does Neurogene have? | As of today, Neurogene has 107 employees. |
| Who is the CEO of Neurogene? | Neurogene's CEO is Dr. Rachel McMinn, PhD. |
| Is Neurogene publicy listed? | Yes, Neurogene is a public company listed on NAS. |
| What is the stock symbol of Neurogene? | Neurogene trades under NGNE ticker. |
| When did Neurogene go public? | Neurogene went public in 2023. |
| Who are competitors of Neurogene? | Similar companies to Neurogene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Neurogene? | Neurogene's current market cap is $243M |
| What is the current revenue of Neurogene? | Neurogene's last 12 months revenue is $0.5M. |
| What is the current EV/Revenue multiple of Neurogene? | Current revenue multiple of Neurogene is -67.4x. |
| Is Neurogene profitable? | Yes, Neurogene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
